High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia

J Am Coll Cardiol. 2018 May 15;71(19):2270-2271. doi: 10.1016/j.jacc.2018.03.448.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anemia, Iron-Deficiency / blood
  • Anemia, Iron-Deficiency / drug therapy*
  • Anemia, Iron-Deficiency / epidemiology
  • Dose-Response Relationship, Drug
  • Ferric Compounds / administration & dosage*
  • Ferric Compounds / adverse effects*
  • Heart Failure / blood
  • Heart Failure / drug therapy*
  • Heart Failure / epidemiology
  • Humans
  • Hypophosphatemia / blood
  • Hypophosphatemia / chemically induced*
  • Hypophosphatemia / epidemiology
  • Infusions, Intravenous
  • Maltose / administration & dosage
  • Maltose / adverse effects
  • Maltose / analogs & derivatives*
  • Pilot Projects
  • Prospective Studies
  • Stroke Volume / drug effects*
  • Stroke Volume / physiology

Substances

  • Ferric Compounds
  • ferric carboxymaltose
  • Maltose

Associated data

  • ClinicalTrials.gov/NCT03079518